USPSTF Releases Final Recommendations on Use of Breast Cancer Prevention Drugs


The US Preventive Services Task Force has recommended that breast cancer primary prevention drugs be offered to higher-risk women at low risk of side effects.

Memorial Sloan Kettering’s Chief of Breast Cancer Medicine, Clifford Hudis, is available to discuss the recommendations, how they align with the recommendations of other cancer organizations, and the way the guidelines might play out in the clinic with patients.


For more information and to set up an interview, contact the Media Staff.